Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Allentown, Basking Ridge, Commack, Harrison, Miami, Middletown, and New York, United StatesSee the 7 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 30 people enrolled
- Started
- 22 Apr 2015
- Expected to end
- Apr 2027
- Type of study
- Interventional
- Treatments tested
- Meclofenamate
- Record updated
- 29 May 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age 18-80
- KPS ≥ 60
- At least one recurrent or progressive brain metastasis (es) from any solid primary tumor that is visible on MRI as assessed by the patient's treating physician
- Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable
- There is no limit on the number of brain metastases
- Surgical resection or SRS to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated
- Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist
Who cannot take part
- Surgery less than two weeks before enrollment
- Concurrent anti-coagulation therapy
- Steroid dose increased in the most recent two weeks
- Progressive systemic disease
- Active Intracranial Hemorrhage
- GI hemorrhage (active or in recent 6 months)
- Active bleeding diathesis
- Allergy to meclofenamate or other NSAID
- Cardiac Arrhythmia requiring medical management and/or pacemaker
- Known congestive heart failure requiring medical management
- Concurrent anti-platelet therapy
- Platelet count ≤ 70,000/mm3
- International normalized ratio (INR) > 1.6 and a Partial Thromboplastin Time (PTT) > 40 seconds
- Serum Creatinine >2 mg/dL OR CrCL <30ml/min
- AST or ALT > 200 U/L
- Hemoglobin <8 g/dL
- Inability to get brain MRI +/- contrast
- Known leptomeningeal metastases
- Primary Brain tumor
- Inability to tolerate PO dosing
- Pregnancy
Where in United States
- Lehigh Valley Health NetworkAllentown, United States
- Memorial Sloan Kettering Cancer CenterBasking Ridge, United States
- Memorial Sloan Kettering Cancer Center at CommackCommack, United States
- Memorial Sloan Kettering WestchesterHarrison, United States
- Baptist Health South FloridaMiami, United States
- Memorial Sloan Kettering MonmouthMiddletown, United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
About the trial
What the trial wants to find out
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis.
Read full original descriptionShow less
This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.
The group in the trial
- MeclofenamateTreatment being tested
All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
- Publications
- Pleiotropic Effects of the NSAID Fenamates on Chloride Channels: Opportunity for Ion Channelopathies?Pharmacology research & perspectives, 2025
- Record updated
- 29 May 2026